StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research report sent to investors on Saturday. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright increased their price target on CASI Pharmaceuticals from $10.00 to $12.00 and gave the stock a buy rating in a […]
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) was upgraded by equities research analysts at William Blair from a “market perform” rating to an “outperform” rating in a report released on Tuesday, MarketBeat Ratings reports. Separately, Wedbush increased their price target on ARS Pharmaceuticals from $5.00 to $13.00 and gave the stock an “outperform” rating in […]
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) was upgraded by equities research analysts at William Blair from a “market perform” rating to an “outperform” rating in a report released on Tuesday, MarketBeat Ratings reports. Separately, Wedbush increased their price target on ARS Pharmaceuticals from $5.00 to $13.00 and gave the stock an “outperform” rating in […]
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) was upgraded by William Blair from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, MarketBeat.com reports. Separately, Wedbush increased their target price on ARS Pharmaceuticals from $5.00 to $13.00 and gave the company an “outperform” rating in a research […]
Analysts at StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a research report issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of TRACON Pharmaceuticals in a research note […]